Share on StockTwits

Stock analysts at Oppenheimer assumed coverage on shares of Bio Blast Pharma (NASDAQ:ORPN) in a report issued on Monday, reports. The firm set an “outperform” rating on the stock.

Shares of Bio Blast Pharma (NASDAQ:ORPN) opened at 7.68 on Monday. Bio Blast Pharma has a 1-year low of $6.61 and a 1-year high of $11.00. The stock’s 50-day moving average is $7.49 and its 200-day moving average is $7.49. The company’s market cap is $109.3 million.

The Fly On The Wall

Receive News & Ratings for Bio Blast Pharma Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio Blast Pharma Ltd and related companies with Analyst Ratings Network's FREE daily email newsletter.